LWLinwei Wang

Linwei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Linwei Wang has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estimating duration in sex work from cross-sectional studies: a Bayesian global synthesis suggests shorter durations

    by Jesse Knight, Siyi Wang, Linwei Wang, Sharmistha Mishra

    Durations selling sex are key determinants of HIV/STI transmission dynamics and service coverage. Such durations are usually estimated from cross-sectional surveys of people actively selling sex. However, cross-sectional surveys are more likely to include individuals selling sex for longer, and survey-reported durations will be right-censored. Prior works have not adequately addressed these two competing biases. In this paper, we derive the mathematical relationship between the distribution of durations reported in cross-sectional surveys and the distribution of true durations in the population overall. These distributions will be identical if true durations are exponentially distributed; otherwise, reported durations will typically underestimate the variance in true durations. We develop a parametric Bayesian model of this relationship, and apply it to re-analyze aggregate data from a global systematic review. Our model-estimated average true durations selling sex are significantly shorter than previously published for all regions — e.g. in Africa: 2.1 (95% CI: 1.8–2.5) versus 5.5 years; in Asia: 1.4 (1.2–1.5) versus 2.8–4.0 years. Shorter average durations then suggest that HIV incidence in sex work could be higher than previously thought, to match the same HIV prevalence data. Our approach can be applied beyond sex work, to characterize duration distributions for any transient risk/disease state.

  • Open Access

    Examining the interaction between area-level immunity coverage and individual-level immunity to help quantify indirect herd benefits: a population-based retrospective cohort study of COVID-19 diagnoses and deaths

    by Linwei Wang, Sarah Swayze, Arjumand Siddiqi, Stefan D Baral, Beate Sander, Hind Sbihi, Jeffrey C Kwong, Sharmistha Mishra

    Empirical evidence on the indirect herd benefits of COVID-19 vaccination and/or prior infection is limited. We examined how area-level immunity interacts with individual-level immunity to affect COVID-19 diagnoses and deaths. Ontario residents aged ≥18 years were followed from August 1, 2021, to January 30, 2022. Individual-level immunity was defined as receipt of a primary series of COVID-19 vaccines or a positive SARS-CoV-2 test in the past 165 days. Area-level immunity was based on the proportion of immune individuals in an individual's residing area. Logistic regression and cause-specific hazard models were used to examine the relationship between immunity and COVID-19 diagnosis, and between immunity and COVID-19 death, with an interaction term between individual-level and area-level immunity. Of 11 122 816 adults, 7 518 015 (67.6%) were classified as having individual-level immunity at baseline. After accounting for potential confounders, area-level immunity (highest vs. lowest quintiles) was associated with lower odds of COVID-19 diagnosis. Higher area-level immunity (highest vs. lowest quintiles) was also associated with lower hazard of COVID-19 death among non-immune individuals (hazard ratio, 0.77 [0.60, 1.00]). Findings provide evidence supporting the herd benefits of vaccination or prior infection on COVID-19 diagnosis and deaths, and provide insights for interpreting vaccine effectiveness estimates in the context of herd immunity.


  • Open Access

    Supervised machine learning to quantitatively assess the prognostic value of tumor-infiltrating lymphocytes in gastric cancer

    by Yinghao Luo, Yuanyuan Chen, Qian Xu, Honglei Chen, Jingping Yuan, Chunwei Peng, Linwei Wang

    With growing insights into the tumor immune microenvironment, tumor-infiltrating lymphocytes (TILs) have emerged as key indicators of anti-tumor immunity.

  • Open Access

    Social inequalities in COVID-19 death by area-level income in 11.2 million people in Ontario, Canada: patterns over time and the mediating role of vaccination

    by Linwei Wang, Sarah Swayze, Korryn Bodner, Andrew Calzavara, Sean P Harrigan, Arjumand Siddiqi, Stefan D Baral, Peter C Austin, Janet Smylie, Maria Koh, et al.

    Knowledge of patterns in COVID-19 deaths by area-level income over time and the mediating role of vaccination in inequality patterns remains limited. We used data from a population-based retrospective cohort of 11 248 572 adults in Ontario, Canada. Cause-specific hazard models were used examine the relationship between income (2016 Census at the dissemination area level) and COVID-19 deaths between March 1, 2020 and January 30, 2022, stratified by wave. We used regression-based causal mediation analyses to examine the mediating role of vaccination in the relationship between income and COVID-19 deaths during waves 4 and 5. After accounting for demographics, baseline health, and other social determinants of health, inequalities in COVID-19 deaths by income persisted over time (HR [95% CI] comparing lowest income vs highest income quintiles were 1.37 [0.98-1.92] for wave 1, 1.21 [0.99-1.48] for wave 2, 1.55 [1.22-1.96] for wave 3, and 1.57 [1.15-2.15] for waves 4 and 5). By the start of wave 4, 7 534 259 (67.7%) of those alive were vaccinated, with lower odds of vaccination in the lowest income vs highest income quintiles (0.71 [0.70-0.71]). This inequality in vaccination accounted for 56.9% [22.5%-91.3%] of inequalities in COVID-19 deaths between individuals in the lowest income vs highest income quintiles. Efforts are needed to address vaccination gaps and residual heightened risks associated with lower income to improve health equity in COVID-19 outcomes.


  • Open Access

    Quantitative observational evidence of indirect herd benefits from COVID-19 vaccination or prior infection on SARS-CoV-2 infections and COVID-19 deaths: a population-based retrospective cohort study in Ontario, Canada

    by Linwei Wang, Sarah Swayze, Arjumand Siddiqi, Stefan D. Baral, Beate Sander, Hind Sbihi, Jeffrey C. Kwong, Sharmistha Mishra

    Background Empirical evidence on the indirect herd benefits of COVID-19 vaccination and/or prior infection is limited. We aimed to examine how area-level immunity interacts with individual-level immunity to affect COVID-19 diagnoses and deaths. Methods Ontario residents aged ≥18 years were followed from August-01-2021 to January-30-2022. Individual-level immunity was defined as received a primary series of COVID-19 vaccines or a positive SARS-CoV-2 test in the past 165 days. Area-level immunity was determined based on the proportion of immune individuals in an individual’s residing area. We used logistic regression and cause-specific hazard models to examine the relationship between immunity and COVID-19 diagnosis, and between immunity and COVID-19 death, respectively. We included an interaction term between individual-level and area-level immunity in each model. Results Of 11,122,816 adults, 7,518,015 (67.6%) were immune at baseline. After accounting for individual-level demographics, baseline health, and area-level social determinants of health, area-level immunity (highest vs. lowest quintiles) was associated with lower odds of COVID-19 diagnosis; the association was larger among non-immune (odds ratios [95% confidence interval]: 0.72 [0.70, 0.75]) than immune individuals (0.93 [0.90, 0.96]). Higher area-level immunity (highest vs. lowest quintiles) was also associated with lower hazard of COVID-19 death among non-immune individuals (hazard ratio: 0.77 [0.60, 1.00]). Conclusions Our study provides observational evidence supporting the herd benefits of vaccination or prior infection on SARS-CoV-2 infections and COVID-19 deaths. Findings reinforce the need for high vaccination coverage to protect vaccinated and unvaccinated populations, while providing insights for interpreting vaccine effectiveness estimates in the context of herd immunity. Main points Using area-level immunity coverage as a proxy for herd immunity, our study demonstrates observational evidence of indirect herd benefits from vaccination and/or prior infection on SARS-CoV-2 infections and COVID-19 deaths. Moreover, herd benefits are greater among non-immune individuals.

  • Open Access

    The Clinical Severity of COVID-19 Variants of Concern: Retrospective Population-Based Analysis

    by Sean P Harrigan, Héctor A Velásquez García, Younathan Abdia, James Wilton, Natalie Prystajecky, John Tyson, Chris Fjell, Linda Hoang, Jeffrey C Kwong, Sharmistha Mishra, et al.

    Background: SARS-CoV-2 variants of concern (VOCs) emerged and rapidly replaced the original strain worldwide. The increased transmissibility of these new variants led to increases in infections, hospitalizations, and mortality. However, there is a scarcity of retrospective investigations examining the severity of all the main VOCs in presence of key public health measures and within various social determinants of health (SDOHs). Objective: This study aims to provide a retrospective assessment of the clinical severity of COVID-19 VOCs in the context of heterogenous SDOHs and vaccination rollout. Methods: We used a population-based retrospective cohort design with data from the British Columbia COVID-19 Cohort, a linked provincial surveillance platform. To assess the relative severity (hospitalizations, intensive care unit [ICU] admissions, and deaths) of Gamma, Delta, and Omicron infections during 2021 relative to Alpha, we used inverse probability treatment weighted Cox proportional hazard modeling. We also conducted a subanalysis among unvaccinated individuals, as assessed severity differed across VOCs and SDOHs. Results: We included 91,964 individuals infected with a SARS-CoV-2 VOC (Alpha: n=20,487, 22.28%; Gamma: n=15,223, 16.55%; Delta: n=49,161, 53.46%; and Omicron: n=7093, 7.71%). Delta was associated with the most severe disease in terms of hospitalization, ICU admissions, and deaths (hospitalization: adjusted hazard ratio [aHR] 2.00, 95% CI 1.92-2.08; ICU: aHR 2.05, 95% CI 1.91-2.20; death: aHR 3.70, 95% CI 3.23-4.25 relative to Alpha), followed generally by Gamma and then Omicron and Alpha. The relative severity by VOC remained similar in the unvaccinated individual subanalysis, although the proportion of individuals infected with Delta and Omicron who were hospitalized was 2 times higher in those unvaccinated than in those fully vaccinated. Regarding SDOHs, the proportion of hospitalized individuals was higher in areas with lower income across all VOCs, whereas among Alpha and Gamma infections, 2 VOCs that cocirculated, differential distributions of hospitalizations were found among racially minoritized groups. Conclusions: Our study provides robust severity estimates for all VOCs during the COVID-19 pandemic in British Columbia, Canada. Relative to Alpha, we found Delta to be the most severe, followed by Gamma and Omicron. This study highlights the importance of targeted testing and sequencing to ensure timely detection and accurate estimation of severity in emerging variants. It further sheds light on the importance of vaccination coverage and SDOHs in the context of pandemic preparedness to support the prioritization of allocation for resource-constrained or minoritized groups.


  • Changes and Features of Indian Diplomacy in the Context of the US Indo-Pacific Strategy

    by Asia Social Science Academy, Rui Wang, Linwei Wang

    During the Trump administration (January 2017 to December 2020), the United States formulated the “Indo-Pacific Strategy” and officially established a strategic competition with China throughout the government. The strategy aimed to woo allies and partners in the Indo-Pacific region and accelerate the construction and promotion of the “Quadrilateral Security Dialogue”. India, as the “world's largest democracy”, has unresolved border issues with China, making it a key target for the United States to woo, and thus forcing India to change its foreign policy. On February 11, 2022, the Biden administration introduced a new version of the “Indo-Pacific Strategy”, which further clarified the overall framework of strategic competition with China, continued to deepen the strategic setting with the prominent features of wooing allies and confronting China, emphasized the core role of the Quad and the central position of ASEAN countries, highlighted the military deterrence of the US-UKAustralia alliance, and created an “anti-China circle” in multiple fields such as biosecurity, science and technology, economic finance, and climate change. Although India is the founding country of the Non-Aligned Movement and has long relied on “independent and autonomous” foreign policy, the current new geopolitical environment where Sino-Indian relations are at a low point due to the border issue, Russia-Ukraine conflicts continue due to NATO's eastward expansion, and the rapid development of the Quad, signifies the power balance in the Asia-Pacific and Indian Ocean regions. This also indirectly reflects the progress of India's own “Indo-Pacific Strategy” and the implementation of the US “Indo-Pacific Strategy”, thus providing a dimension for predicting the development trend of the strategic competition between China and the US.

  • Tumor immune microenvironment components and the other markers can predict the efficacy of neoadjuvant chemotherapy for breast cancer

    by Weiqian Zhang, Ke Xu, Zhengfa Li, Linwei Wang, Honglei Chen

    Breast cancer is an epithelial malignant tumor that occurs in the terminal ducts of the breast. Neoadjuvant chemotherapy (NACT) is an important part of breast cancer treatment. Its purpose is to use systemic treatment for some locally advanced breast cancer patients, to decrease the tumor size and clinical stage so that non-operable breast cancer patients can have a chance to access surgical treatment, or patients who are not suitable for breast-conserving surgery can get the opportunity of breast-conserving. However, some patients who do not respond to NACT will lead deterioration in their condition. Therefore, prediction of NACT efficacy in breast cancer is vital for precision therapy. The tumor microenvironment (TME) has a crucial role in the carcinogenesis and therapeutic response of breast cancer. In this review, we summarized the immune cells, immune checkpoints, and other biomarkers in the TME that can evaluate the efficacy of NACT in treating breast cancer. We believe that the detection and evaluation of the TME components in breast cancer are helpful to predict the efficacy of NACT, and the prediction methods are in the prospect. In addition, we also summarized other predictive factors of NACT, such as imaging examination, biochemical markers, and multigene/multiprotein profiling.


  • Open Access

    The Clinical Severity of COVID-19 Variants of Concern: Retrospective Population-Based Analysis (Preprint)

    by Sean P Harrigan, Héctor A Velásquez García, Younathan Abdia, James Wilton, Natalie Prystajecky, John Tyson, Chris Fjell, Linda Hoang, Jeffrey C Kwong, Sharmistha Mishra, et al.

    BACKGROUND SARS-CoV-2 variants of concern (VOCs) emerged and rapidly replaced the original strain worldwide. The increased transmissibility of these new variants led to increases in infections, hospitalizations, and mortality. However, there is a scarcity of retrospective investigations examining the severity of all the main VOCs in presence of key public health measures and within various social determinants of health (SDOHs). OBJECTIVE This study aims to provide a retrospective assessment of the clinical severity of COVID-19 VOCs in the context of heterogenous SDOHs and vaccination rollout. METHODS We used a population-based retrospective cohort design with data from the British Columbia COVID-19 Cohort, a linked provincial surveillance platform. To assess the relative severity (hospitalizations, intensive care unit [ICU] admissions, and deaths) of Gamma, Delta, and Omicron infections during 2021 relative to Alpha, we used inverse probability treatment weighted Cox proportional hazard modeling. We also conducted a subanalysis among unvaccinated individuals, as assessed severity differed across VOCs and SDOHs. RESULTS We included 91,964 individuals infected with a SARS-CoV-2 VOC (Alpha: n=20,487, 22.28%; Gamma: n=15,223, 16.55%; Delta: n=49,161, 53.46%; and Omicron: n=7093, 7.71%). Delta was associated with the most severe disease in terms of hospitalization, ICU admissions, and deaths (hospitalization: adjusted hazard ratio [aHR] 2.00, 95% CI 1.92-2.08; ICU: aHR 2.05, 95% CI 1.91-2.20; death: aHR 3.70, 95% CI 3.23-4.25 relative to Alpha), followed generally by Gamma and then Omicron and Alpha. The relative severity by VOC remained similar in the unvaccinated individual subanalysis, although the proportion of individuals infected with Delta and Omicron who were hospitalized was 2 times higher in those unvaccinated than in those fully vaccinated. Regarding SDOHs, the proportion of hospitalized individuals was higher in areas with lower income across all VOCs, whereas among Alpha and Gamma infections, 2 VOCs that cocirculated, differential distributions of hospitalizations were found among racially minoritized groups. CONCLUSIONS Our study provides robust severity estimates for all VOCs during the COVID-19 pandemic in British Columbia, Canada. Relative to Alpha, we found Delta to be the most severe, followed by Gamma and Omicron. This study highlights the importance of targeted testing and sequencing to ensure timely detection and accurate estimation of severity in emerging variants. It further sheds light on the importance of vaccination coverage and SDOHs in the context of pandemic preparedness to support the prioritization of allocation for resource-constrained or minoritized groups.

  • Open Access

    HIV- and sex work-related stigmas and quality of life of female sex workers living with HIV in South Africa: a cross-sectional study

    by Claire Chen, Stefan Baral, Carly A. Comins, Mfezi Mcingana, Linwei Wang, Deliwe Rene Phetlhu, Ntambue Mulumba, Vijay Guddera, Katherine Young, Sharmistha Mishra, et al.

    Background: Environmental quality of life (QoL) assesses individually perceived factors such as physical safety and security, accessibility, quality of healthcare, and physical environment. These factors are particularly relevant in the context of sex work and HIV, where stigma has been identified as an important barrier across several prevention and treatment domains. This study aims to examine the association between different types of HIV- and sex work-related stigmas and environmental QoL among female sex workers (FSW) living with HIV in Durban, South Africa. Methods: We conducted cross-sectional analyses using baseline data from the Siyaphambili randomized controlled trial. FSW who reported sex work as their primary source of income and had been diagnosed with HIV for ≥ 6 months were enrolled from June 2018–March 2020, in eThekwini, South Africa. We evaluated the association between environmental QoL, dichotomizing the environmental domain score collected by the WHO Quality of Life HIV Brief (WHOQOL-HIV BREF) questionnaire at the median, and stigma using modified robust Poisson regression models. Five stigma subscales were assessed: sex work-related (anticipated, enacted, or internalized stigma) and HIV-related (anticipated or enacted stigma). Results: Among 1373 FSW, the median environmental QoL was 10.5 out of 20 [IQR: 9.0–12.5; range 4.0–19.0], while the median overall QoL was 3 out of 5 [IQR: 2–4; range 1–5]. One-third of FSW (n = 456) fell above the median environmental QoL score, while 67% were above the median overall QoL (n = 917). Reporting anticipated sex work stigma was associated with lower environmental QoL (adjusted prevalence ratio [aPR] 0.74 [95% CI 0.61, 0.90]), as was severe internalized sex work stigma (aPR: 0.64, 95% CI 0.48, 0.86). Reporting enacted HIV stigma versus none was similarly associated with lower environmental QoL (aPR: 0.65, 95% CI 0.49, 0.87). Enacted sex work stigma and anticipated HIV stigma were not statistically associated with environmental QoL. Conclusions: This study highlights the need to consider the impact of multiple stigmas on FSW’s non-HIV related clinical outcomes, including safety and physical well-being. Moreover, these results suggest that addressing underlying structural risks may support the impact of more proximal HIV prevention and treatment interventions. Trial registration NCT03500172 (April 17, 2018)